|
gptkbp:instance_of
|
gptkb:radio_station
|
|
gptkbp:administered_by
|
injection
|
|
gptkbp:administration_timing
|
before PET scan
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
flutemetamol F18
|
|
gptkbp:chemical_formula
|
C19 H22 F2 N4 O3 S
|
|
gptkbp:clinical_trial
|
gptkb:GE_Healthcare
Phase 3
positive efficacy
|
|
gptkbp:clinical_use
|
neuroimaging
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
hypersensitivity to flutemetamol
|
|
gptkbp:distribution_channels
|
hospital pharmacies
|
|
gptkbp:dosage_form
|
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vizamyl
|
|
gptkbp:indication
|
PET imaging
|
|
gptkbp:ingredients
|
flutemetamol
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
110 minutes
|
|
gptkbp:manufacturer
|
gptkb:GE_Healthcare
|
|
gptkbp:market_approval_year
|
gptkb:2013
|
|
gptkbp:marketed_as
|
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
binds to amyloid plaques
|
|
gptkbp:packaging
|
single-dose vials
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:patient_preparation
|
no special preparation required
|
|
gptkbp:photography
|
positron emission tomography (PET)
|
|
gptkbp:project
|
commercialized
|
|
gptkbp:provides_guidance_on
|
recommended for use in specific cases
|
|
gptkbp:radiation_dose
|
low
|
|
gptkbp:regulatory_compliance
|
prescription only
|
|
gptkbp:research_focus
|
Alzheimer's biomarkers
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:shelf_life
|
up to 12 hours after opening
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
injection site reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:trade
|
gptkb:Vizamyl
|
|
gptkbp:used_for
|
diagnosing Alzheimer's disease
|
|
gptkbp:weight
|
396.46 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Flutemetamol
|
|
gptkbp:bfsLayer
|
6
|